Breast Reconstruction Clinical Trial
Official title:
A Phase 2b/3 Randomized, Prospective, Double Blind, Within-Subject Vehicle Controlled, Multi-Center Study to Determine the Efficacy and Safety of Granexin® Gel in Reducing Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery
Verified date | June 2022 |
Source | Xequel Bio, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate effectiveness of Granexin® gel in reducing scar formation in surgical incisional wounds.
Status | Completed |
Enrollment | 184 |
Est. completion date | May 26, 2022 |
Est. primary completion date | May 26, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Female subjects aged 18 years and older 2. Female subjects of childbearing potential must have a negative urine or blood pregnancy test at screening and baseline. 3. Female subjects of childbearing potential must agree to use ONE of the following birth control methods throughout the study: - abstinence - condom with spermicide - diaphragm with spermicide - Hormonal contraceptive - intra-uterine device Non-childbearing confirmed by prior documentation of at least one of the following: - postmenopausal - surgically sterilized 4. Subjects undergoing a breast surgery procedure with bilateral anchor incisions 5. Signed informed consent form Exclusion Criteria: 1. Subjects with breast implants or history of breast implants 2. Subjects undergoing breast surgery requiring breast implants 3. Subjects requiring nipple grafting using any technique 4. Subjects with a history of infection in the past 6 months in the intended area of incision 5. Subjects with breast tattoos in the intended area of the incision 6. Subjects with known skin sensitivity to Tegaderm™ 7. Subjects with a history of keloids 8. Known conditions of collagen vascular diseases 9. Subjects with clinically significant medical conditions as determined by the Investigator, which would impair wound healing including renal, hepatic, hematologic, neurologic or autoimmune disease. Examples include but are not limited to: 1. Renal insufficiency as an estimated GFR, which is < 30 mL/min/1.7m2 2. Abnormal blood biochemistry defined as 3 times that of the upper limit of the normal range 3. Hepatic insufficiency defined as total bilirubin > 2 mg/dL or serum albumin < 25 g/L 4. Hemoglobin < 9 g/dL 5. Hematocrit < 30% 6. Platelet count < 100,000 µL 10. Any history within the last 5 years or the presence of any active systemic cancer (with the exception of non-melanoma skin cancer) 11. Current treatment with systemic corticosteroids (>15 mg/day). Washout period is 30 days prior to screening 12. Current treatment with biologic immunosuppressive agents or chemotherapeutic agents. Wash out period for short term immunosuppressive agents is 14 days prior to screening 13. Previous history of radiation therapy to the chest 14. Known inability to complete required study visits during study participation 15. A psychiatric condition (e.g., suicidal ideation), chronic alcohol consumption, or drug abuse problem determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance 16. Use of any investigational drug or therapy within the 28 days prior to screening 17. History of previous breast surgeries in the area where the incisions are to be made 18. Currently pregnant, pregnant during the 6 months prior to screening, lactating, or breastfeeding 19. Any other factor, which may, in the opinion of the Investigator, compromise participation and follow-up in the study 20. Any areolar abnormalities that are deemed clinically significant by the Investigator |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University - Feinberg School of Medicine - Division of Plastic & Reconstructive Surgery | Chicago | Illinois |
United States | Iowa Plastic Surgery | Davenport | Iowa |
United States | Universal Axon Clinical Research | Doral | Florida |
United States | Private Clinic- David Kulber | Los Angeles | California |
United States | Miami Plastic Surgery | Miami | Florida |
United States | Luxurgery | New York | New York |
United States | Pasadena Surgeons | Pasadena | California |
United States | University of Utah | Salt Lake City | Utah |
United States | Integrated Aesthetics | Spring | Texas |
United States | Ibrahim H. Amjad, MD, PA | W. Miami | Florida |
United States | Wake Forest Baptist Hospital - Plastic and Reconstructive Surgery | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Xequel Bio, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in scar severity at Month 12 | Assessed using the Patient and Observer Scar Assessment Scale (POSAS). The POSAS has a rage from 6 to 60 with higher scores indicating worse outcomes. One scale will be used for each segment of the scar. The score from each segment will be combined into one score. | Month 12 | |
Secondary | Change in scar severity at Month 6, Month 9 and Month 12 | Assessed using the Scar Cosmesis Assessment and Rating (SCAR) Scale. The SCAR scale has a range of 0 (best possible scar) to 15 (worst possible scar). | Month 6, Month 9 and Month 12 | |
Secondary | Change in scar severity at Month 9 | Assessed using the Patient and Observer Scar Assessment Scale (POSAS). The POSAS has a range from 6 to 60 with higher scores indicating worse outcomes. One scale will be used for each segment of the scar. The score from each segment will be combined into one score. | Month 9 | |
Secondary | Proportion of subjects with incision healing complications | Investigator's assessment of incision healing complications | Day 1 to Month 12 | |
Secondary | Proportion of subjects with incision infection | Investigator's assessment of presence or absence of infection | Day 1 to Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03757793 -
Near-infrared Spectroscopy for Monitoring Tissue Oxygenation in Breast Reconstruction
|
||
Completed |
NCT05491473 -
Negative Pressure in PAP Donor Sites
|
||
Not yet recruiting |
NCT06013514 -
Post-market Prospective Clinical Study of Nagor Perle Mammary Implants
|
||
Completed |
NCT02169011 -
Secondary Breast Reconstruction With a Flap of Skin From the Back
|
N/A | |
Completed |
NCT01216319 -
Evaluation of the Cook Biodesign Plastic Surgery Matrix
|
N/A | |
Not yet recruiting |
NCT00973544 -
Do Closed Suction Drains Affect the Complications Rate of Breast Reconstruction With Silicone Prosthesis?
|
N/A | |
Completed |
NCT01176786 -
Reusable Versus Disposable Draping System in Breast Reconstruction Surgery
|
N/A | |
Active, not recruiting |
NCT00748722 -
Pre-Operative Imaging of Abdominal Wall Perforators Using CT Angiography
|
N/A | |
Completed |
NCT00753922 -
Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses
|
Phase 3 | |
Completed |
NCT05897463 -
Nipple Neurotization
|
||
Recruiting |
NCT05377723 -
Abdominal Scar Improvement in Microsurgical Breast Reconstruction
|
N/A | |
Completed |
NCT04350411 -
Comparison of PEAK PlasmaBlade™ to Conventional Diathermy in Abdominal Based Free Flap Breast Reconstruction
|
N/A | |
Completed |
NCT06321549 -
New Era of DIEP With Minimally Invasive Mastectomy
|
||
Withdrawn |
NCT03135392 -
Sensation After Nipple Sparing Mastectomy and Breast Reconstruction With or Without Neurotized Free Tissue Transfer
|
N/A | |
Completed |
NCT01256502 -
The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery
|
N/A | |
Active, not recruiting |
NCT04715802 -
Options on the Breast Reconstruction Timing and Method After Removal of Polyacrylamide Hydrogel
|
||
Active, not recruiting |
NCT04491591 -
Implementing BREASTChoice Into Practice
|
N/A | |
Recruiting |
NCT04661501 -
BREAST ADM Trial for Alloplastic Breast Reconstruction
|
N/A | |
Suspended |
NCT03625765 -
Integrated Imaging System for In Vivo Visualization of Free Flap Perfusion Using Indocyanine Dye
|
N/A | |
Withdrawn |
NCT00778947 -
Single Centre Study to Compare Harmonic Scalpel to Conventional Diathermy in Free Tissue Transfer Breast Reconstruction
|
N/A |